Venmax Drugs & Pharmaceuticals Limited has notified BSE of an upcoming board meeting scheduled for Thursday, May 14, 2026, at 3.30 P.M. The intimation has been filed in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026.

Board Meeting Details

The following table summarises the key details of the scheduled board meeting:

Trading Window Closure

In conjunction with the board meeting intimation, Venmax Drugs and Pharmaceuticals has also disclosed the status of the trading window for its designated persons. The trading window, which has been closed since April 1, 2026, will continue to remain shut until May 16, 2026. This closure period extends to 48 hours after the approval of the audited standalone financial results for the quarter and year ended March 31, 2026, in line with applicable regulatory requirements.

Filing Details

The intimation was filed by Priyanka Agarwal, Company Secretary & Compliance Officer of Venmax Drugs and Pharmaceuticals Limited, and digitally signed on May 06, 2026. The company is registered at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009.

Venmax drugs & pharmaceuticals Limited has disclosed to BSE that it does not meet the criteria to be classified as a 'Large Corporate' under SEBI's regulatory framework. The company made this disclosure on April 14, 2026, in compliance with SEBI operational circular requirements.

Regulatory Compliance Disclosure

The disclosure was made pursuant to SEBI Circular dated August 10, 2021, which pertains to fund raising by issuance of debt securities by large entities. The company also referenced SEBI Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024 in its communication to the exchange.

Company Status Confirmation

Venmax Drugs & Pharmaceuticals Limited confirmed that as on March 31, 2026, the company does not fulfill the criteria specified in SEBI's circular for Large Corporate classification. This determination affects the company's obligations regarding debt securities issuance and related regulatory requirements.

Corporate Information

The disclosure was signed by Priyanka Agarwal, Company Secretary & Compliance Officer, and submitted to BSE's Head of Listing Compliance Department. The company is headquartered in Hyderabad with its registered office located at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally.

This disclosure ensures transparency regarding the company's regulatory status and compliance with SEBI guidelines for corporate classification and fund raising activities.